Form 8-K - Current report:
SEC Accession No. 0001437749-25-036710
Filing Date
2025-12-03
Accepted
2025-12-03 06:27:22
Documents
13
Period of Report
2025-11-26
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K sava20251201_8k.htm   iXBRL 8-K 26658
  Complete submission text file 0001437749-25-036710.txt   159954

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sava-20251126.xsd EX-101.SCH 3580
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE sava-20251126_def.xml EX-101.DEF 11808
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sava-20251126_lab.xml EX-101.LAB 15859
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sava-20251126_pre.xml EX-101.PRE 12023
15 EXTRACTED XBRL INSTANCE DOCUMENT sava20251201_8k_htm.xml XML 2968
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41905 | Film No.: 251544945
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)